Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly immunotherapy, but it is burdened by a lot of debt. Read more here.

HIDDEN under the shadow of an Ikea superstore, this so-called ‘caravan city’ reveals the stark reality of life for those without a home to even furnish. Freezing in below-zero ...

“So when I put into my very helpful DeepSeek, what famous picture ... quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here ...

S&P 500 futures pared an early gain fueled by Treasury Secretary Scott Bessent’s comment that the Trump administration is ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

Through the third quarter ... picture in a meaningful way. To me, oncology represents a hugely important new area for Lilly, and one that is ripe for disruption given the size of the addressable ...

Bristol Myers Squibb said it will slash $2 billion in costs by the end of 2027, expanding its ongoing cost-savings effort to chart a path toward long-term growth. The company also issued full ...